05:11 PM EDT, 07/17/2025 (MT Newswires) -- Citius Oncology ( CTOR ) closed a $9 million public offering of shares and warrants.

The company sold almost 6.82 million shares and related warrants at $1.32 apiece.

Proceeds will support Lymphir commercialization, including license payments, and be used for working capital and general corporate purposes, the company said Thursday in a statement.

Citius Oncology ( CTOR ) is a majority-owned subsidiary of Citius Pharmaceuticals ( CTXR ) .